Publication | Closed Access

An FDA/CDER perspective on nonclinical testing strategies: Classical toxicology approaches and new approach methodologies (NAMs)

Fda/cder PerspectivePreclinical Drug EvaluationPharmacologyToxicology TestingDrug TestToxicologyNew Approach MethodologiesDrug TrialMedicineClassical Toxicology ApproachesIntegrated Testing Strategy